Intron A

(Interferon Alfa-2b)

ApprovedSmall molecule

Interferon Alfa-2b is used to treat certain cancers like melanoma and hepatitis C, and some viral infections by helping the immune system fight off disease.[2] Intron A is currently approved and in use across 32 indications[4].[1]

Intron A is one of 713 small molecule programs targeting HIV infection. It is currently in Approved.

Indications

Total Trials

Active Trials

712

Competitors

Pipeline

Status by Indication[4][1]

Indication

HIV InfectionActive, not recruiting

MetastasisActive, not recruiting

Clear Cell Renal CarcinomaActive, not recruiting

Hepatitis B Virus InfectionUnknown

Kidney CancerActive, not recruiting

Cutaneous T-Cell LymphomaActive, not recruiting

Cutaneous MelanomaActive, not recruiting

Hairy Cell LeukemiaUnknown

LeukemiaActive, not recruiting

Metastatic MelanomaActive, not recruiting

HIV InfectionPhase 3

Active, not recruiting

MetastasisPhase 3

Active, not recruiting

Clear Cell Renal CarcinomaPhase 2

Active, not recruiting

Hepatitis B Virus InfectionPreclinical

Unknown

Kidney CancerPhase 2

Active, not recruiting

Cutaneous T-Cell LymphomaApproved

Active, not recruiting

Cutaneous MelanomaPhase 3

Active, not recruiting

Hairy Cell LeukemiaPreclinical

Unknown

LeukemiaPhase 1

Active, not recruiting

Metastatic MelanomaPhase 1

Active, not recruiting

Showing 10 of 32 indications

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Intron A

Merck & Co.

Approved

27 2

Bnt162b2

BioNTech

Preclinical

29 3

Stivarga

Bayer

Preclinical

1 4

Aimovig

Amgen

Preclinical

1 5

Calciferol

Alnylam Pharmaceuticals

Activella

Achromycin V

WWyeth-Lederle Vaccines

Glucocorticoid

1 9

HB-Admscs

HHope Biosciences Research Foundation

Preclinical

4 10

MRNA COVID-19 Vaccine

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Melanoma

NCT00003641

Clinical

Trials by Indication[1]

Melanoma4 trials

Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma

Withdrawn·NNeoPlas Innovation·Phase 2·NCT00963664·250 enrolled

Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma

Completed·OOhio State University Comprehensive Cancer Center·Phase 1·NCT01462773·16 enrolled

Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma

Completed·NNational Cancer Institute, Naples·Phase 3·NCT01359956·269 enrolled

Show 1 more trial

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Active, not recruiting·EECOG-ACRIN Cancer Research Group·Phase 3·NCT00003641·1,150 enrolled

Chronic Hepatitis3 trials

Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016)

Completed· Merck & Co. logo

Merck & Co.·Phase 2/3·NCT03537274·1,224 enrolled

Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C

Completed·MMedtronic Corporate Technologies and New Ventures·Phase 2·NCT00919633·116 enrolled

Combination Therapy With Interferon Plus Interleukin 2 and Hepatitis B Vaccine in Chronic Hepatitis B Patients

Completed·TTongji Hospital·Phase 4·NCT02360592·94 enrolled

Kaposi's sarcoma2 trials

The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001114·90 enrolled

A Phase I Trial of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (rHuGM-CSF), Recombinant Alpha Interferon and Azidothymidine (AZT) in AIDS-Associated Kaposi's Sarcoma

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000694·18 enrolled

Minimal Residual Disease1 trial

Interferon α for the Therapy of Minimal Residual Disease

Unknown status·PPeking University People's Hospital·N/A·NCT02185261·81 enrolled

Leukemia1 trial

Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma

Completed·UUniversity of Miami·Phase 2·NCT02737046·15 enrolled

16 more indications

Renal Cell Carcinoma1 trial

Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00561912·2 enrolled

Locally Advanced or Metastatic Solid Tumors1 trial

A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors

Completed· Roche logo

Roche·Phase 1·NCT02174172·158 enrolled

Pancreatic Cancer1 trial

Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00059826·89 enrolled

Hepatitis C1 trial

Subcutaneous Continuous Infusion of Interferon Alfa-2b and Ribavirin in Hepatitis C Genotype 1 Nonresponders

Completed·FFoundation for Liver Research·Phase 2/3·NCT00624325·30 enrolled

Treatment1 trial

Structured Treatment Interruptions With or Without Pegylated Interferon Alpha for HIV-Infected Patients After Prolonged Viral Suppression

Terminated·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 3·NCT00125814·200 enrolled

Cutaneous T-cell lymphoma1 trial

Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas

Terminated·PPolish Lymphoma Research Group·Phase 4·NCT02323659·100 enrolled

Kidney Cancer1 trial

Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer

Unknown status·UUniversity of Aarhus·Phase 2·NCT01274273·118 enrolled

Intraepithelial Neoplasia1 trial

Topical Interferon Alfa 2b and Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia

Completed·CCoordinación de Investigación en Salud, Mexico·Phase 4·NCT02199327·18 enrolled

Metastatic Melanoma1 trial

IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT01409174·19 enrolled

Chronic Myelogenous Leukemia1 trial

Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)

Terminated· Merck & Co. logo

Merck & Co.·Phase 2/3·NCT03547154·344 enrolled

HIV infection1 trial

The Safety and Effectiveness of a Two-Drug Combination in the Treatment of Patients With Hepatitis C Plus Advanced HIV Infections

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001035·10 enrolled

Ovarian Cancer1 trial

Chemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian Cancer

Completed·LLeiden University Medical Center·Phase 1/2·NCT01639885·15 enrolled

Adult T-Cell Leukemia/lymphoma1 trial

Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma

Terminated·UUniversity of Miami·Phase 4·NCT00854581·13 enrolled

Progressive Multifocal Leukoencephalopathy1 trial

A Pilot Study of the Efficacy of Recombinant Alpha Interferon (IFN-A2b) and Zidovudine (AZT) in the Treatment of Progressive Multifocal Leukoencephalopathy (PML) Complicating HIV-1 Infection

Completed·UUniversity of Miami·N/A·NCT00002270

Adjuvant Treatment1 trial

αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies

Completed·DDavid Bartlett·Phase 1/2·NCT02151448·64 enrolled

Unspecified1 trial

Differences in Evoked Intracellular Interferon Signaling Pathways Using Single Cell Phosphoprotein Profiling

Completed·UUniversity of North Carolina, Chapel Hill·Phase 1·NCT01217359·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 27 trial records for Interferon Alfa-2b. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Intron A drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Interferon Alfa-2b compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Interferon Alfa-2b. EMBL-EBI & Wellcome Sanger Institute.
[5]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Interferon Alpha/beta Receptor Agonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Merck & Co.

Intron A

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Melanoma4 trials

Chronic Hepatitis3 trials

Kaposi's sarcoma2 trials

Minimal Residual Disease1 trial

Leukemia1 trial

Renal Cell Carcinoma1 trial

Locally Advanced or Metastatic Solid Tumors1 trial

Pancreatic Cancer1 trial

Hepatitis C1 trial

Treatment1 trial

Cutaneous T-cell lymphoma1 trial

Kidney Cancer1 trial

Intraepithelial Neoplasia1 trial

Metastatic Melanoma1 trial

Chronic Myelogenous Leukemia1 trial

HIV infection1 trial

Ovarian Cancer1 trial

Adult T-Cell Leukemia/lymphoma1 trial

Progressive Multifocal Leukoencephalopathy1 trial

Adjuvant Treatment1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News